Highlights
- Clever Culture Systems (ASX:CC5) reported developments during 2026.
- The company published its FY26 Annual Report in August 2026 and provided a company presentation in September.
- Clever Culture Systems operates from Adelaide and maintains sales and service presences in the United States and Europe.
- The November 18, 2026 share price was AUD 0.016, unchanged.
Clever Culture Systems develops automated laboratory systems for interpreting microbial culture plates, including its APAS technology. Clever Culture Systems (ASX:CC5) closed unchanged at AUD 0.016 on November 18, 2026. Its 2026 disclosures included full-year reporting, quarterly operating updates and discussions of its PSC Biotech partnership, as the Business continues working on laboratory adoption, installations and related commercial activities.
Clever Culture Systems Business and Operations
Clever Culture Systems develops automated laboratory technology for microbiology. Its APAS platform is designed to automate image interpretation and reading of microbial culture plates for clinical and pharmaceutical laboratory workflows. APAS is intended to help laboratories interpret microbial culture plate images, requiring integration with existing workflows.
Clever Culture Systems 2026 Company Updates
The company published its FY26 annual report in August 2026 and provided a company presentation in September. Its investor centre also lists a first-quarter FY27 activities and cash-flow report and an October 2026 investor discussion concerning its Partnership with PSC Biotech. The company’s quarterly disclosures and PSC Biotech discussions address both operating progress and the commercial route to customers.
Clever Culture Systems Financial and Operational Context
Clever Culture Systems operates from Adelaide and maintains sales and service presences in the United States and Europe. Its materials feature customer discussions involving major pharmaceutical-sector laboratory operations, providing context for its focus on laboratory automation, though individual customer communications should not be interpreted as guarantees of future orders. Sales and service presences in the United States and Europe provide geographical context without establishing the Volume of customer demand.
Industry Conditions and Key Risks
Instrument adoption depends on installation cycles, lab validation, budgets, service support and repeat utilisation. Commercial partnerships can expand access to users without automatically translating into recognised Revenue or positive cash flow. Instrument purchasing decisions, installation and validation may take place at different times from discussions with commercial partners.
What to Watch Next
Further company disclosures can clarify APAS instrument installations, customer validation, utilisation and service or consumables income. The partnership with PSC Biotech may provide commercial access, but the relevant evidence will be customer contracts, delivered systems and recognised revenue where disclosed. Quarterly cash reports can also indicate whether revenue receipts are keeping pace with operating expenditure. Commercial milestones should be distinguished from presentations and partnership discussions until the company reports measurable outcomes.
Key Insights
Clever Culture Systems (ASX:CC5) continues to develop automated microbiology reading systems and has discussed its PSC Biotech partnership in 2026 investor materials. Adoption in laboratory workflows depends on installation, user validation and ongoing service requirements. Subsequent operational reporting, sales recognition and cash-flow disclosures will show the extent to which these activities contribute to its reported business performance.



_11_18_2026_07_37_18_094902.jpg)


Please wait processing your request...